Method of preparing antibodies to characterize oncogenes
AssigneeMassachusetts Institute of Technology
InventorsRobert A. Weinberg, Clifford J. Tabin, Scott M. Bradley
Life of this patent
Estimating the term…
Loading patent…
AssigneeMassachusetts Institute of Technology
InventorsRobert A. Weinberg, Clifford J. Tabin, Scott M. Bradley
Estimating the term…
Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly.sup.12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, seralogical reagents, such as antibody specific for either p21 protein expressed from the proto-oncogene or oncogene, or a common site therein, are described.
A method of producing antibodies capable of detecting whether a wild-type allele has been mutated to a mutant allele, comprising:
A method of producing antibody capable of detecting carcinogenesis caused by mutation of a proto-oncogene into an oncogene, comprising:
A method of producing antibodies specific for a protein encoded by an oncogene or a protein encoded by its corresponding proto-oncogene, but not for both, comprising the steps of:
A method of producing antibodies capable of determining whether a proto-oncogene has been mutated to its corresponding oncogene, comprising the steps of:
Dependencies are inferred from the claim text.